1. Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma

   • Marco K. C. Hui
   • Kenneth K. Y. Lai
   • Simon Law

   Original Paper Open access 19 April 2012 Pages: 3009 - 3016

   

2. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study

   • Tao Zhao
   • Hao Chen
   • Tingrong Zhang

   Original Paper 05 April 2012 Pages: 3017 - 3023

   

3. Expression of interleukin-17 and its clinical significance in gastric cancer patients

   • Xin Ying Meng
   • Chang Hong Zhou
   • Ping Ji

   Original Paper 29 June 2012 Pages: 3024 - 3028

   

4. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine

   • Jingwei Yu
   • Jing Gao
   • Lin Shen

   Original Paper 06 July 2012 Pages: 3029 - 3034

   

5. Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer

   • Amir Sonnenblick
   • Yakir Rottenberg
   • Ayala Hubert

   Original Paper 08 July 2012 Pages: 3035 - 3038

6. C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients

   • Jing Gao
   • Yunzhi Dang
   • Lin Shen

   Original Paper 20 July 2012 Pages: 3039 - 3045

   

7. Downregulation of GRIM-19 is associated with hyperactivation of p-STAT3 in hepatocellular carcinoma

   • Feifei Li
   • Wanhua Ren
   • Chengyong Qin

   Original Paper 11 April 2012 Pages: 3046 - 3054

   

8. MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients

   • Yousri M. Hussein
   • Fouad E. Morad
   • Nermin Raafat

   Original Paper 01 June 2012 Pages: 3055 - 3062

   

9. Growth arrest-specific homeobox is associated with poor survival in patients with hepatocellular carcinoma

   • Peng Zhou
   • Zhi Chen
   • Zhi-Ming Wang

   Original Paper 27 May 2012 Pages: 3063 - 3069

   

10. Overexpression of RPS6KB1 predicts worse prognosis in primary HCC patients

    • Pin Dong Li
    • Wen Jie Zhang
    • Hui Yun Wang

    Original Paper 10 June 2012 Pages: 3070 - 3076

    

11. Involvement of discoidin domain 1 receptor in recurrence of hepatocellular carcinoma by genome-wide analysis

    • Zhi-Xiang Jian
    • Jian Sun
    • Yi-Long Wu

    Original Paper 30 June 2012 Pages: 3077 - 3082

    

12. Tumor necrosis factor-α (TNF-α) stimulates the epithelial–mesenchymal transition regulator Snail in cholangiocarcinoma

    • Anchalee Techasen
    • Nisana Namwat
    • Puangrat Yongvanit

    Original Paper 19 August 2012 Pages: 3083 - 3091

    

13. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer

    • De-shen Wang
    • Hui-yan Luo
    • Rui-hua Xu

    Original Paper 05 April 2012 Pages: 3092 - 3100

    

14. Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer

    • Ludmila Katherine Martin
    • Lai Wei
    • Tanios Bekaii-Saab

    Original Paper 24 June 2012 Pages: 3101 - 3107

    

15. Clinical significance of miR-22 expression in patients with colorectal cancer

    • Guangjun Zhang
    • Shusen Xia
    • Tong Zhou

    Original Paper 11 April 2012 Pages: 3108 - 3112

    

16. The quantitative analysis by stem-loop real-time PCR revealed the microRNA-34a, microRNA-155 and microRNA-200c overexpression in human colorectal cancer

    • Mojin Wang
    • Peng Zhang
    • Xiaofeng Sun

    Original Paper 05 May 2012 Pages: 3113 - 3118

    

17. Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer

    • Mevlüde İnanç
    • Özlem Er
    • Ferhan Elmalı

    Original Paper 12 May 2012 Pages: 3119 - 3124

18. Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography

    • Zeki Ustuner
    • O. Meltem Akay
    • Zafer Gulbas

    Original Paper 14 June 2012 Pages: 3125 - 3128

19. Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male

    • Ming-Wei Chen
    • Shuai Ye
    • You-Min Wang

    Original Paper 03 July 2012 Pages: 3129 - 3135

20. Expression of MSP58 in human colorectal cancer and its correlation with prognosis

    • Hai Shi
    • Shu-Jun Li
    • Chang-Sheng Chen

    Original Paper Open access 08 July 2012 Pages: 3136 - 3142

    

21. New strategy in hepatic metastatic colorectal cancer: tomotherapy and capecitabine followed by hepatic surgical resection

    • W. Cacheux
    • M. A. Bollet
    • P. Mariani

    Short Communication 02 August 2012 Pages: 3143 - 3146

    

22. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients

    • Emin Tamer Elkiran
    • Mehmet Ali Kaplan
    • Anatolian Society of Medical Oncology Group

    Original Paper 22 June 2012 Pages: 3147 - 3154

    

23. Desmoplastic malignant mesothelioma originating from the peritoneum

    • Hiroyuki Takamaru
    • Yoshiaki Arimura
    • Yasuhisa Shinomura

    Letter to the Editor 29 June 2012 Pages: 3155 - 3156

    

24. Clinicopathological significance of lymphatic vessel density marked by D2-40 and E-cadherin expression in non-small-cell lung cancer

    • Shidai Jin
    • Wei Zhu
    • Renhua Guo

    Original Paper 18 April 2012 Pages: 3157 - 3161

    

25. Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma

    • Haofei Wang
    • Wujun Wang
    • Xuhui Gao

    Original Paper 22 April 2012 Pages: 3162 - 3168

    

26. Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma

    • Yosuke Togashi
    • Katsuhiro Masago
    • Michiaki Mishima

    Original Paper 11 April 2012 Pages: 3169 - 3175

    

27. Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer

    • Georg Holgersson
    • Martin Sandelin
    • Michael Bergqvist

    Original Paper 08 May 2012 Pages: 3176 - 3182

    

28. Expression and clinical significance of GRIM-19 in lung cancer

    • Xiao-Yun Fan
    • Zi-Feng Jiang
    • Rong-Yu Liu

    Original Paper 10 May 2012 Pages: 3183 - 3189

    

29. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients

    • Han-Bo Le
    • Wang-Yu Zhu
    • Yong-Kui Zhang

    Original Paper 11 July 2012 Pages: 3190 - 3197

    

30. Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC

    • Angela Zupa
    • Giulia Vita
    • Giuseppina Improta

    Original Paper 08 July 2012 Pages: 3198 - 3201

    

31. Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group

    • Hiroyuki Nakamura
    • Hiroaki Satoh
    • Kinya Furukawa

    Original Paper 02 November 2012 Pages: 3202 - 3206

    

32. High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy

    • Dongliang Zhu
    • Xiaoming Zha
    • Yujie Sun

    Original Paper 29 April 2012 Pages: 3207 - 3215

    

33. Association of p73 G4C14-A4T14 polymorphisms with genetic susceptibilities to breast cancer: a case–control study

    • Xin Zhou
    • Chengyi Wu

    Original Paper 26 April 2012 Pages: 3216 - 3221

    

34. Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients

    • Guo-Chun Zhang
    • Xue-Ke Qian
    • Ning Liao

    Original Paper 01 May 2012 Pages: 3222 - 3231

    

35. Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience

    • Erkan Dogan
    • Hikmet Yorgun
    • Yavuz Ozisik

    Original Paper 22 May 2012 Pages: 3232 - 3239

36. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer

    • Minqing Wu
    • Weidong Wei
    • Xiaoming Xie

    Original Paper 04 June 2012 Pages: 3240 - 3249

    

37. Rural–urban disparities in use of post-lumpectomy radiation

    • Steve R. Martinez
    • Dhruvil R. Shah
    • Richard J. Bold

    Original Paper 09 June 2012 Pages: 3250 - 3257

38. Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells

    • Ping Li
    • Artour Torossian
    • Shen Fu

    Original Paper 23 June 2012 Pages: 3258 - 3264

    

39. Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot study

    • Ozgur Tanriverdi
    • Nezih Meydan
    • Sabri Barutca

    Original Paper 30 June 2012 Pages: 3265 - 3271

40. BRCA1/BRCA2 gene mutations/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity

    • Abida Juwle
    • Dhananjaya Saranath

    Original Paper 03 July 2012 Pages: 3272 - 3281

    

41. Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression

    • Fausto Petrelli
    • Sandro Barni

    Review Article 28 July 2012 Pages: 3282 - 3290

    

42. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI

    • Kwonoh Park
    • Jae-Lyun Lee
    • Hanjong Ahn

    Original Paper 30 March 2012 Pages: 3291 - 3297

    

43. Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma

    • Atsunari Kawashima
    • Akira Tsujimura
    • The Osaka Renal Cell Carcinoma Clinical Study Collaboration

    Original Paper 29 April 2012 Pages: 3298 - 3305

    

44. Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion

    • Jian-Jun Ma
    • Ling-Min Kong
    • Ting-Yi Bao

    Original Paper 13 June 2012 Pages: 3306 - 3313

    

45. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database

    • Alexandr Poprach
    • Zbyněk Bortlíček
    • Jakub Gregor

    Original Paper 30 June 2012 Pages: 3314 - 3320

    

46. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma

    • Tomas Buchler
    • Tomas Pavlik
    • Bohuslav Melichar

    Short Communication 30 June 2012 Pages: 3321 - 3324

    

47. Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma

    • Guangning Zhao
    • Yuming Yang
    • Yan Sun

    Original Paper 03 August 2012 Pages: 3325 - 3334

    

48. A coincidence of renal cell carcinoma and hematological malignancies

    • Gokhan Sargın
    • Irfan Yavasoglu
    • Zahit Bolaman

    Letter to the Editor 29 July 2012 Pages: 3335 - 3338

49. Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer

    • Qiang Fu
    • Judd W. Moul
    • Thomas J. Polascik

    Original Paper 12 June 2012 Pages: 3339 - 3344

    

50. Detection of hyaluronidase RNA and activity in urine of schistosomal and non-schistosomal bladder cancer

    • Sanaa Eissa
    • Hanan Shehata
    • Omar El-Ahmady

    Original Paper 04 July 2012 Pages: 3345 - 3351